Critical Contrast: Jasper Therapeutics (NASDAQ:JSPR) versus DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Volatility & Risk

DBV Technologies has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Insider & Institutional Ownership

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 1.9% of DBV Technologies shares are owned by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares DBV Technologies and Jasper Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-815.73%	-106.07%	-76.17%
Jasper Therapeutics	N/A	-67.64%	-58.53%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for DBV Technologies and Jasper Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	0	0	2	0	3.00
Jasper Therapeutics	0	0	9	0	3.00

DBV Technologies currently has a consensus price target of $22.50, suggesting a potential upside of 404.48%. Jasper Therapeutics has a consensus price target of $62.50, suggesting a potential upside of 1,092.75%. Given Jasper Therapeutics’ higher possible upside, analysts plainly believe Jasper Therapeutics is more favorable than DBV Technologies.

Valuation and Earnings

This table compares DBV Technologies and Jasper Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$15.73 million	5.83	-$72.73 million	($4.50)	-0.99
Jasper Therapeutics	N/A	N/A	-$64.46 million	($4.86)	-1.08

Jasper Therapeutics has lower revenue, but higher earnings than DBV Technologies. Jasper Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Jasper Therapeutics beats DBV Technologies on 9 of the 12 factors compared between the two stocks.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.